Hypercholesterolaemia: not all cases warrant treatment.
نویسندگان
چکیده
منابع مشابه
Drug treatment of hypercholesterolaemia.
We review the current drug treatment of hyperlipidaemia at our specialist out-patient clinics between October 1995 and December 1995. During this period, 523 patients received one or more lipid-lowering drugs. Each patient was assessed for his vascular risk, the number of lipid measurements before and after treatment and the type, duration and outcome of drug treatment. Only 30% patients achiev...
متن کاملNot all bad treatment is psychological maltreatment.
One of the conceptual and definitional issues that has plagued the study of child maltreatment is the relationship between intention and outcome. This paper flows from the finding that the common developmentally destructive element in all forms of child maltreatment is psychological maltreatment, that the study of child abuse and neglect is the study of child maltreatment in a fundamental way. ...
متن کاملTreatment of the arthropathy of familial hypercholesterolaemia.
A 29-year-old woman suffering from the arthropathy of familial hypercholesterolaemia was treated with a fat-modified low-cholesterol diet and colestipol. Symptomatic improvement occurred in association with a moderate reduction in the plasma cholesterol concentration. The pathogenesis of the musculoskeletal features of this disease is reviewed, and the implications of this patient's therapeutic...
متن کاملHypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo.
OBJECTIVE To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hypercholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocholesterolaemic controls. DESIGN Parallel group comparison and double blind randomised crossover. SETTING University hospital. PATIENTS Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and ...
متن کاملHypercholesterolaemia: optimal treatment by next-generation drugs?
ticular, homozygous autosomal dominant hypercholesterolaemia, an orphan disease caused by mutations in the LDL receptor, apolipoprotein B (APOB), or PCSK9, is characterised by elevated LDL-C levels [8]. At the same time as the approval of evolocumab, the US Food and Drug Administration (FDA) approved another PCSK9 inhibitor, alirocumab (Praluent) produced by Sanofi and Regeneron. Alirocumab was...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1993
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.307.6912.1125